PainReform announces ‘favorable’ safety profile of PRF-110

PainReform announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110’s “promising” safety profile, with maximum blood levels recorded at approximately 10% of the FDA-established safety threshold. “The safety data we’ve observed with PRF-110 is highly encouraging and supports our belief in its potential to enhance patient care in surgical settings,” said Ehud Geller, Chairman and interim CEO of PainReform. “With its favorable safety profile and the ability to use higher doses, PRF-110 has the potential to address significant unmet needs in postoperative pain management, well beyond just herniorrhaphy and bunionectomy, thereby reducing reliance on opioids and improving overall patient outcomes across a wide range of surgical procedures.”